Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Combination Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma
NCT04161248Phase 1Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Sep 2020
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of venetoclax, glofitamab and tafasitamab in B cell lymphoma (3 arms), sponsored by Canadian Cancer Trials Group. Primary endpoints: Maximum Tolerated Dose at 4 years and Recommended Phase II Dose at 4 years. Started Sep 2020; status: active, not recruiting.
02
Drugs
venetoclaxglofitamabtafasitamab
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT04161248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04161248.